Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
MAKO's Cash to Debt is ranked higher than
97% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. MAKO: No Debt )
MAKO' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.71
MAKO's Equity to Asset is ranked higher than
73% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. MAKO: 0.71 )
MAKO' s 10-Year Equity to Asset Range
Min: -1.52   Max: 0.93
Current: 0.71

-1.52
0.93
Interest Coverage No Debt
MAKO's Interest Coverage is ranked higher than
88% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. MAKO: No Debt )
MAKO' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 20.68
M-Score: -3.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -34.58
MAKO's Operating margin (%) is ranked lower than
52% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 6.75 vs. MAKO: -34.58 )
MAKO' s 10-Year Operating margin (%) Range
Min: -17214.29   Max: -34.58
Current: -34.58

-17214.29
-34.58
Net-margin (%) -31.69
MAKO's Net-margin (%) is ranked lower than
52% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.06 vs. MAKO: -31.69 )
MAKO' s 10-Year Net-margin (%) Range
Min: -16852.38   Max: -31.69
Current: -31.69

-16852.38
-31.69
ROE (%) -23.11
MAKO's ROE (%) is ranked higher than
51% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. MAKO: -23.11 )
MAKO' s 10-Year ROE (%) Range
Min: -55.75   Max: -23.11
Current: -23.11

-55.75
-23.11
ROA (%) -19.50
MAKO's ROA (%) is ranked higher than
51% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. MAKO: -19.50 )
MAKO' s 10-Year ROA (%) Range
Min: -227.95   Max: -19.5
Current: -19.5

-227.95
-19.5
ROC (Joel Greenblatt) (%) -63.71
MAKO's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 12.75 vs. MAKO: -63.71 )
MAKO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1752.75   Max: -63.71
Current: -63.71

-1752.75
-63.71
Revenue Growth (%) 25.10
MAKO's Revenue Growth (%) is ranked higher than
96% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. MAKO: 25.10 )
MAKO' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 213.3
Current: 25.1

0
213.3
EBITDA Growth (%) -17.30
MAKO's EBITDA Growth (%) is ranked higher than
63% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. MAKO: -17.30 )
MAKO' s 10-Year EBITDA Growth (%) Range
Min: -56.1   Max: 171.4
Current: -17.3

-56.1
171.4
EPS Growth (%) -14.60
MAKO's EPS Growth (%) is ranked higher than
64% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. MAKO: -14.60 )
MAKO' s 10-Year EPS Growth (%) Range
Min: -57.5   Max: 86.9
Current: -14.6

-57.5
86.9
» MAKO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

MAKO Guru Trades in Q1 2013

Steven Cohen 2,548 sh (New)
Jim Simons 1,487,600 sh (+362.71%)
Mario Gabelli 244,900 sh (+13.7%)
John Keeley Sold Out
Manning & Napier Advisors, Inc Sold Out
» More
Q2 2013

MAKO Guru Trades in Q2 2013

Steven Cohen 8,200 sh (+221.82%)
Mario Gabelli 299,700 sh (+22.38%)
Jim Simons 708,300 sh (-52.39%)
» More
Q3 2013

MAKO Guru Trades in Q3 2013

Mario Gabelli 706,600 sh (+135.77%)
Jim Simons Sold Out
Steven Cohen Sold Out
» More
Q4 2013

MAKO Guru Trades in Q4 2013

Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MAKO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2013-12-31 Sold Out 0.12%$29.55 - $29.99 $ 29.990%0
Mario Gabelli 2013-09-30 Add 135.77%0.07%$11.61 - $29.5 $ 29.9999%706600
Mario Gabelli 2013-06-30 Add 22.38%$10.33 - $12.81 $ 29.99164%299700
John Keeley 2013-03-31 Sold Out $10.76 - $13.17 $ 29.99155%0
John Burbank 2012-12-31 Sold Out 0.12%$12.09 - $17.78 $ 29.99109%0
John Keeley 2012-12-31 New Buy$12.09 - $17.78 $ 29.99109%75
John Burbank 2012-09-30 New Buy0.12%$12.18 - $26.46 $ 29.9985%150000
Mario Gabelli 2012-09-30 Add 33.68%0.01%$12.18 - $26.46 $ 29.9985%194900
Mario Gabelli 2012-06-30 Add 23.87%0.01%$21.37 - $42.5 $ 29.99-3%145800
Mario Gabelli 2011-09-30 Add 45.31%0.01%$21.41 - $40.48 $ 29.99-9%83700
Mario Gabelli 2011-06-30 New Buy0.01%$23.51 - $34.66 $ 29.997%57600
George Soros 2011-06-30 Sold Out $23.51 - $34.66 $ 29.997%0
George Soros 2011-03-31 New Buy$14.1 - $21.75 $ 29.9966%9800
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 14.56
MAKO's P/B is ranked lower than
75% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. MAKO: 14.56 )
MAKO' s 10-Year P/B Range
Min: 2.45   Max: 19.71
Current: 14.56

2.45
19.71
P/S 13.10
MAKO's P/S is ranked lower than
80% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. MAKO: 13.10 )
MAKO' s 10-Year P/S Range
Min: 4.24   Max: 49.41
Current: 13.1

4.24
49.41
EV-to-EBIT -30.67
MAKO's EV-to-EBIT is ranked lower than
90% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 20.80 vs. MAKO: -30.67 )
MAKO' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -30.67

Valuation & Return

vs
industry
vs
history
Price/Net Cash 107.10
MAKO's Price/Net Cash is ranked lower than
89% of the 117 Companies
in the Global Medical Devices industry.

( Industry Median: 13.75 vs. MAKO: 107.10 )
MAKO' s 10-Year Price/Net Cash Range
Min: 3.82   Max: 142.28
Current: 107.1

3.82
142.28
Price/Net Current Asset Value 37.02
MAKO's Price/Net Current Asset Value is ranked lower than
78% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 8.80 vs. MAKO: 37.02 )
MAKO' s 10-Year Price/Net Current Asset Value Range
Min: 3.36   Max: 40.14
Current: 37.02

3.36
40.14
Price/Tangible Book 15.38
MAKO's Price/Tangible Book is ranked lower than
79% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. MAKO: 15.38 )
MAKO' s 10-Year Price/Tangible Book Range
Min: 2.7   Max: 20.56
Current: 15.38

2.7
20.56
Price/Median PS Value 1.11
MAKO's Price/Median PS Value is ranked higher than
61% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. MAKO: 1.11 )
MAKO' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 3.32
Current: 1.11

0.38
3.32
Forward Rate of Return (Yacktman) -29.48
MAKO's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. MAKO: -29.48 )
MAKO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 22.3   Max: 55.8
Current: -29.48

22.3
55.8

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:4M6.Germany
MAKO Surgical Corporation was incorporated in Delaware in November 2004. The Company is a medical device company that markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures. It offers MAKOplasty, an innovative, restorative surgical solution that enables orthopedic surgeons to consistently, reproducibly and precisely treat patient specific, osteoarthritic disease. The Company currently offers MAKOplasty Partial Knee Arthroplasty, or MAKOplasty PKA, and MAKOplasty Total Hip Arthroplasty, or MAKOplasty THA. MAKOplasty PKA, which requires extraction and replacement of the entire joint, enables resurfacing of one or two specific diseased compartments of the joint, preserving significantly more soft tissue and healthy bone of the knee. MAKOplasty procedures are enabled through its proprietary technology consisting of the components which includes its RIO system, its MAKOplasty applications, and its RESTORIS family of implant systems. The centerpiece of MAKOplasty is the RIO system, its proprietary robotic arm, interactive, orthopedic system, that provides both pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal and accurate implant insertion and alignment. The RIO system consists of two elements: a tactile robotic arm utilizing an integrated bone cutting instrument and a patient specific visualization component. The RIO system, version 2.0 of its Tactile Guidance System, or TGS, represents an important expansion from its first generation TGS, enabling and expanding the MAKOplasty PKA application to multicompartmental resurfacing procedures, allowing orthopedic surgeons to treat degenerative knee osteoarthritis from early-stage, unicompartmental degeneration through mid-stage, multicompartmental degeneration with a modular knee implant system, as well as enabling the MAKOplasty THA application. The Company's MAKOplasty PKA application enables surgeons to isolate and resurface just one or two specific diseased compartments of the joint through a minimally invasive incision, preserving significantly more soft tissue and healthy bone of the knee. The MAKOplasty knee resurfacing procedure is performed by the surgeon using the surgical planning and execution software integrated into its patient specific visualization system. The Company's MAKOplasty THA application utilizes the RIO system's tactile, visual and auditory feedback to assist the surgeon in preparing the acetabulum (hip socket) for optimal placement of the acetabular cup implant. The MAKOplasty THA application allows the surgeon to preoperatively plan the placement of the hip implants on a three dimensional image of a pre-operative CT scan. Its RESTORIS family of knee implants is designed to enable minimally invasive restoration of one or two of the diseased compartments of the knee joint. Its RESTORIS family of knee implants for use in si

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide